Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial

AIMS: Although heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause for hospitalization, its overall costs remain unclear. Therefore, we assessed the health care‐related costs of ambulatory HFpEF patients and the effect of spironolactone. METHODS AND RESULTS: The aldosteron...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashemi, Djawid, Dettmann, Ludwig, Trippel, Tobias D., Holzendorf, Volker, Petutschnigg, Johannes, Wachter, Rolf, Hasenfuß, Gerd, Pieske, Burkert, Zapf, Antonia, Edelmann, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261555/
https://www.ncbi.nlm.nih.gov/pubmed/31984661
http://dx.doi.org/10.1002/ehf2.12606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261555/
https://www.ncbi.nlm.nih.gov/pubmed/31984661
http://dx.doi.org/10.1002/ehf2.12606

Ejemplares similares